New cancer drug combo tested in advanced tumors

NCT ID NCT05147272

Terminated Disease control Sponsor: Debiopharm International SA Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety of a new oral drug called RP-6306 when combined with the chemotherapy gemcitabine in adults with advanced solid tumors that had stopped responding to other treatments. The main goal was to find the highest dose patients could tolerate without severe side effects and to see if the combination showed any signs of fighting the cancer. The trial was terminated after enrolling 67 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

# 1004, Memorial Sloan Kettering Cancer Institute

New York, New York, 10065, United States
# 1008, Columbia University

New York, New York, 10032, United States
# 1010, University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
# 1016, Mayo Clinic

Rochester, Minnesota, 55902, United States
# 1017, Mayo Clinic

Jacksonville, Florida, 32224, United States
# 1018, Mayo Clinic

Phoenix, Arizona, 85054, United States
# 1019, UCLA, Westwood Cancer Center

Los Angeles, California, 90095, United States
# 1022, Moffitt Cancer Center

Tampa, Florida, 33612, United States
# 1023, START Midwest

Grand Rapids, Michigan, 49546, United States
# 2001, Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2C1, Canada
# 3003, Sarah Cannon Research Institute

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

ADULT SOLID TUMOR